Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment - Wikidata - thesis-toulmin - TriplyDB

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

http://www.wikidata.org/entity/Q36338254

about

Therapeutic potential of intracerebroventricular replacement of modified human β-hexosaminidase B for GM2 gangliosidosis Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Targeted approaches to induce immune tolerance for Pompe disease therapy The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies Can pluripotent stem cells be used in cell-based therapy?Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo Strategies to compare clinical antitherapeutic antibody data when changing assay platforms: a case study.Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins.Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease.AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease Toward reducing immunogenicity of enzyme replacement therapy: altering the specificity of human β-glucuronidase to compensate for α-iduronidase deficiency.Immune Tolerance Strategies in Siblings with Infantile Pompe Disease-Advantages for a Preemptive Approach to High-Sustained Antibody Titers.Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.Enzyme replacement in the CSF to treat metachromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector Gene therapy approaches for lysosomal storage disease: next-generation treatment.Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis.Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients.Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients.Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy.Unwanted immunogenicity: lessons learned and future challenges.Fabry disease, enzyme replacement therapy and the significance of antibody responses.Immunogenicity of therapeutic proteins: influence of aggregation.Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy.Development of interferon beta-neutralising antibodies in multiple sclerosis--a systematic review and meta-analysis.Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins.Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy.30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case.Enzyme enhancers for the treatment of Fabry and Pompe disease.Mannose 6-phosphate conjugation is not sufficient to allow induction of immune tolerance to phenylalanine ammonia-lyase in dogs.

P2860

Q24597943-8714EE5F-78DA-4535-83D1-0B8D6D2CF174 Q24650910-0ADB7C74-A9E1-43AD-8110-C856E8D5AE86 Q26738810-4941BBED-445D-4FE3-A0D2-F28DFFD01D26 Q26767363-76C6E616-5EF5-4542-83FF-49A069B43265 Q26851666-175B3DEC-6B0B-48E2-81A8-493EEDBF12E9 Q27002327-A6FC5E90-778A-4448-8999-A476E65C6FAD Q28066498-220B9536-F37D-429B-8BD0-45CA4EB4E03B Q30614255-2D171F9D-7F4B-4A9C-9D1B-7188A3F6B155 Q30987208-9C4AB11B-0F93-4D51-8801-C9FAB1EB273B Q33784812-472C610B-1AF2-4801-BDEA-A0E8974C8777 Q34541550-53C61C1F-6A54-46A5-AD2C-6408F3669749 Q35070412-BAB3BC92-14DF-4FD0-B3FE-701F7F4BC522 Q35123163-9CFC9789-D026-4038-85C1-5F1ADAABFF52 Q35153203-AF89334B-6A97-4B1B-93F3-F88094B968AC Q35732635-7E416519-15B8-4498-AD3D-88C65A8BE2E8 Q35759492-99C30768-07BF-4000-BFF0-9715E5AD7C39 Q35836295-40E055C6-34A2-4053-A03A-103F067F053C Q35911463-B1138BEA-92C7-40F9-8C6D-B7F5D30A2CB2 Q35964228-43F028C9-BDDE-4375-8311-DB42EB75D022 Q36147475-0C282FA5-7F13-4549-9CAE-DC31BEE527D3 Q36201277-4E3FFD18-B8A6-413A-A000-9B8632323BD5 Q36640081-AFAD0821-88B5-4F85-A5F2-B4F2A9C7BF52 Q36784566-D0D8B01C-811D-49A0-A00A-F58E1184C0C1 Q36867296-F3F33261-5309-44BD-9837-79FBB027796E Q37012107-7B1E9C52-6ACF-4D0E-BB8F-9C81F24B4ACB Q37097386-CB1A74C1-3DF2-4695-8286-13ABD447A06F Q37374502-8DE5967C-6783-435D-ACE0-114B9A09AA7D Q37657164-58782D1C-28B1-4D72-8169-6F994630427D Q37670302-520D18B6-8B6E-44A7-AA75-700ABA1440BA Q37810215-BE064B7D-56C9-48B2-87DC-E91D31445E98 Q37950838-1B570400-4767-482B-BFB0-9ACCBAD333E2 Q38126938-F72D2759-84F2-4AF3-9528-9E34E800BE9F Q38453644-FDCAEB62-BA87-4980-B7FD-6780DAF66E3D Q38565662-E940E7FD-AEF6-4F11-8BBD-A37A9E2993BF Q38680881-FE32689B-C6F1-4379-AD3A-917CBCC2BEFE Q38684097-9E85CBE4-4D9D-4114-9054-0558FA63AF16 Q39505508-8A890885-FF81-4A57-AE0A-41149E5ED295 Q41466662-0A1DBBD4-33E6-4968-9FA6-01A07C17AB0F Q42018342-296312E3-C787-4848-85F3-D5174842C89E Q42257752-8522F0ED-E0AE-4F2C-B716-8381AB3A6E00

P2860

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

http://www.wikidata.org/entity/Q36338254

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Neutralizing antibodies to the ...... ting, prevention and treatment

@ast

Neutralizing antibodies to the ...... ting, prevention and treatment

@en

type

label

Neutralizing antibodies to the ...... ting, prevention and treatment

@ast

Neutralizing antibodies to the ...... ting, prevention and treatment

@en

prefLabel

Neutralizing antibodies to the ...... ting, prevention and treatment

@ast

Neutralizing antibodies to the ...... ting, prevention and treatment

@en

P1433

Q36338254-6E618AFF-1A5D-4231-9EB5-A579297BB1DC

P1476

Q36338254-3A023A0E-8B9E-404D-8851-917465A42216

P2093

Q36338254-23294B2D-8F07-48E1-9ABA-C49207F1F7EE

Q36338254-253CBE15-675A-4827-9BDA-0846CCBBEBBF

Q36338254-2BFC0560-2986-451D-949C-E742D56EE8F0

Q36338254-3870CECB-0A8F-44A0-9CE5-A61FE90E6E40

Q36338254-892990E1-5878-4A4E-A1CC-76DDB52E1935

Q36338254-8DA000A3-F2B1-4E18-9098-58632201B01F

Q36338254-ABCE0D82-6942-4F62-9D3E-7F0856DE783A

Q36338254-E28199DE-0B8B-4AFB-AC15-E513C202C103

P2860

Q36338254-0583FB59-C036-4D1D-B039-9EC7387CA97A

Q36338254-06F1EAC9-43DD-4F43-AA4F-51A9250658A7

Q36338254-098E1C16-B27A-4D3F-93A9-32DFBE2EEFAE

Q36338254-0AD1B00C-0642-4F63-B035-27627764EACF

Q36338254-0CECAE11-5F32-4EE3-8946-1B910F74B226

Q36338254-10205A20-59C8-40D7-AA06-E80ED0719481

Q36338254-12207DB1-0A10-426E-916E-335D77D710A1

Q36338254-183729FB-6ACE-4CDF-9243-DD035848E679

Q36338254-249D4DAC-4A1D-46B8-8686-19C8B1E22D36

Q36338254-264D609F-1EA1-4FC7-A617-B7A2479E02AA

P2888

Q36338254-89D7726E-42A9-4B4B-8D6F-5662C51BD873

P304

Q36338254-C02E0B8F-8B3E-4127-903A-AA1ADE823626

P31

Q36338254-6A1B5679-6385-4F3B-B847-80E1063DED6C

P356

Q36338254-14614A2B-06B8-46CF-9A1C-A2884552A36E

P433

Q36338254-05204C0C-1E54-4196-9096-57956832D99C

P478

Q36338254-77C4F907-0AF9-4DA4-8195-80C707752A03

P577

Q36338254-AD0D92F7-B8B8-4760-B314-FFB0FFC496C7

P5875

Q36338254-4D85C000-3023-433E-B929-34C80FBB8861

P698

Q36338254-E2275C98-B034-4326-99DA-3E6DDEAB49B5

P921

Q36338254-D774DB1E-7793-41CA-B89F-E61726AFB665

P932

Q36338254-9C0A2C76-AA45-4FC1-8FC6-F7C4B4DD1606

P356

P1433

Nature Biotechnology

P1476

Neutralizing antibodies to the ...... ting, prevention and treatment

@en

P2093

Amy Rosenberg

http://www.w3.org/2001/XMLSchema#string

Anne Pariser

http://www.w3.org/2001/XMLSchema#string

Daniela Verthelyi

http://www.w3.org/2001/XMLSchema#string

Elizabeth Shores

http://www.w3.org/2001/XMLSchema#string

Gibbes Johnson

http://www.w3.org/2001/XMLSchema#string

Jay Lozier

http://www.w3.org/2001/XMLSchema#string

Jinhai Wang

http://www.w3.org/2001/XMLSchema#string

Susan Kirshner

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Mannose 6-phosphate receptors: new twists in the tale

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation

An essential role for Scurfin in CD4+CD25+ T regulatory cells

The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion.

Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.

Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions.

P2888

P304

901-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1484

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23157036

http://www.w3.org/2001/XMLSchema#string

P698

18688246

http://www.w3.org/2001/XMLSchema#string

P921

P932

3478093

http://www.w3.org/2001/XMLSchema#string